Income from operations stood at Rs 5479 crore which is a six per cent increase YoY.  Ebitda stood at Rs 1243 crore, an increase of 22.7 per cent. PAT stood at 729 crore an increase of 13.3 per cent.

Key Highlights of the Quarter

One India: Overall business grew by 13% YoY led by sustained momentum across core therapies and traction in flagship brands; modest contribution from covid portfolio

SAGA: South Africa private business grew 16% YoY growth in ZAR terms; maintains market beating trajectory in secondary terms

US business: Reported US $150Mn revenue; Robust momentum in core formulation business; strong traction in respiratory portfolio

New approval: Lanreotide injection 505 (b)(2); expands peptide portfolio

R&D investments stand at INR 262 crore; Priority development projects spend on track

Growth in operating profitability and prudent working capital management drives continued healthy net cash positive position at December-21.

One India Business

Overall business grew by 13% YoY in INR terms

The branded prescription business continued the market beating growth for the 3^rd consecutive quarter in FY22 driven by sustained traction across therapies in core portfolio; modest contribution from covid portfolio

Trade generics businesswitnessed strong demand across regions leading to high traction across flagship brands and key therapeutic categories

Consumer health business witnessed robust traction in anchor brands & transitioned brands

SAGA—South Africa, Sub-Sahara Africa and Global Access

South Africa private business grew 16% YoY in ZAR terms and maintains market beating trajectory in secondary terms; tender business performed in-line with expectations

SSA:Healthy order flow across regions; fastest growing company in Kenya as per IQVIA MAT November 2021

CGA: Performance in-line with expectations; strong demand traction continues for TLD

North America

Robust momentum in core formulation business with YoY growth of 7% in USD terms; strong traction in respiratory portfolio with YoY growth of 36%¹ in USD terms

In Albuterol, Cipla’s TRx market share stood at 15.9% of the overall market as per IQVIA week ending 21^st December 2021

In Arformoterol, Cipla’s TRx market stood at 26.8% of the overall market as per IQVIA week ending 21^st December 2021

New approval: Lanreotide injection 505 (b)(2); expands peptide portfolio.

International Markets: (Emerging Markets and Europe) & API

International markets: Maintained scale supported by strong DTM growth across geographies, steady double digit growth in secondary terms during the quarter

Two respiratory products filed in Europe

API Performance attributed to momentary slowdown in orders from developed markets. Traction in orders from emerging markets; medium-term orderbook robust. Continued traction with global seedings & lock-ins.

According to Umang Vohra, MD and Global CEO, Cipla, “I am pleased to see the strong launch and commercial momentum across our core markets during the quarter. Our portfolio execution in branded markets of India and South Africa and strong respiratory traction driving our US generic franchisee to a multi-quarter high quarter were key drivers. The unlocking of our first 505(b)(2) peptide asset lanreotide injection is an important step in strengthening our complex generic engine inching up our US footprint. Our EBITDA margin for the quarter came in at 22.7 per cent and given the YTD traction we are well placed to close the year in line with our guidance of 22 per cent.